Kite extends collaboration with MaxcytePublished: March 4, 2019
MaxCyte, a US-based global life sciences company, has announced that it has entered into a multi-drug clinical and commercial agreement with Kite, a Gilead Company.
Kite first entered into research agreement with MaxCyte in November last year to use MaxCyte’s Flow Electroporation Technology (FET) for non-viral cell engineering purposes. Under the terms of the renewed agreement, Kite will use the technology to develop multiple CAR-T drug candidates for up to 10 targets. In return, MaxCyte will receive development and approval milestones and sales-based payments in addition to other licensing fees.
Flow electroporation is used in gene editing and gene delivery and allows almost any molecule to be delivered into any cell with minimal cell disturbance. FET is MaxCyte’s core program and currently it is being used by most of the leading global biopharmaceutical companies for cell delivery. It has more than 70 partnered program licenses in cell therapy including more than 35 licensed for clinical use.
MaxCyte is also developing CARMA therapies, mRNA-based proprietary therapeutic platform for autologous cell therapy, for its own pipeline. Its first drug candidate is in a Phase 1 clinical trial for mesolthelin-expressing solid tumors.
Doug Doerfler, President & CEO of MaxCyte commented: “We’re excited to take our relationship with Kite further into product development, providing the company the ability to leverage MaxCyte’s versatile cell engineering platform to enable the power of gene-editing for clinical and commercial development of critical new CAR-T therapeutics”.
Source: MaxCyte Announces Multi-Drug Clinical & Commercial Agreement with Kite, a Gilead Company; Press Release